|Bid||1.5500 x 21500|
|Ask||1.5600 x 21500|
|Day's Range||1.5500 - 1.6025|
|52 Week Range||1.3800 - 3.7100|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we...
Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, N.J. and BOCA RATON, Fla., July 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration (“FDA”) recently completed a Pre-Approval Inspection (